Invivyd, Inc. (IVVD) Stock Analysis and Metrics

Invivyd

NASDAQ: IVVD

$0.61 ▼ 0.00 (-0.36%)

At close: Jul 27, 2026 · 9:42 AM UTC

Financial Ratios

Market Cap103.78 Mn

P/E-1.83

P/S1.94

Div. Yield0.00

Revenue Growth (1y) (Qtr)24.51

Add ratio to table…

About

Invivyd, Inc. is a biopharmaceutical company focused on the discovery development and commercialization of monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases. The company’s initial target is COVID 19 with plans to expand into respiratory syncytial virus and measles. Its lead product PEMGARDA received emergency use authorization from the U S Food and Drug Administration in March 2024 for pre exposure prophylaxis of COVID 19 in immunocompromised adults and adolescents. Invivyd is advancing a next generation monoclonal antibody candidate VYD2311 for COVID 19 and has preclinical programs for respiratory syncytial virus and measles. The company leverages a proprietary antibody discovery platform and a partnership with Adimab to engineer half life extended molecules designed to retain activity against evolving virus variants. Invivyd’s strategy centers on delivering protection to vulnerable populations by creating antibodies that can be updated quickly as new variants emerge. The firm also invests in variant monitoring and structural analysis to inform its engineering efforts. Through internal research and external collaborations it seeks to build a broad pipeline of product candidates that address multiple high need viral threats.

Invivyd generates revenue principally from the sale of PEMGARDA to specialty distributors and directly to infusion centers healthcare providers and provider institutions in the United States. During the year ended December 31 2025 the company recorded net product revenue from sales to three specialty distributors that accounted for 46 percent 23 percent and 17 percent of total gross sales. In addition to product sales the company receives milestone payments from its collaboration agreements with Adimab and may earn royalties on net sales of licensed products. Future revenue streams may include sales of VYD2311 upon regulatory approval milestone payments from collaborations and royalties on licensed technologies. The company does not currently operate manufacturing facilities and relies on contract manufacturing organizations for drug substance and drug product supply. Invivyd has entered into long term master services agreements with WuXi Biologics to secure manufacturing capacity for PEMGARDA and VYD2311. These agreements provide for the purchase of drug substance and drug product for both clinical and commercial supply. The firm also works with third party logistics providers to distribute its product to end users of care.

Invivyd competes in the monoclonal antibody and antiviral markets alongside large pharmaceutical companies such as AstraZeneca Roche Merck Pfizer Gilead and biotechnology firms developing COVID 19 therapies. It also faces competition from vaccine manufacturers Moderna Pfizer BioNTech Novavax and from other prophylactic antibodies targeting respiratory syncytial virus and measles. The company’s competitive advantages stem from its proprietary antibody discovery platform its exclusive access to Adimab’s B cell mining and antibody engineering capabilities and its focus on half life extended molecules that aim to reduce viral escape. Invivyd benefits from Fast Track designation for VYD2311 and from a proactive variant monitoring program that informs its engineering efforts. The firm’s partnership with Adimab provides access to industry leading antibody mining optimization and developability screening tools. Invivyd’s approach emphasizes the identification of broadly neutralizing antibodies that target conserved epitopes on the spike protein reducing the risk of viral escape. The company also leverages its experience with adintrevimab and PEMGARDA to accelerate preclinical and clinical development of new candidates. These factors position the company to address unmet needs in immunocompromised populations and to respond quickly to emerging virus strains.

The company serves immunocompromised patients who receive care from hematology oncology rheumatology and transplant specialists. Its customers include healthcare providers infusion centers hospitals and provider institutions that administer PEMGARDA under medical supervision. Distribution is handled through three major specialty distributors that sell the product to end user sites of care. While the filing does not disclose the specific names of these distributors it notes that they collectively represent the majority of gross sales. Invivyd’s customer base is concentrated in the United States where the emergency use authorization for PEMGARDA applies. The firm also engages with academic medical centers and specialty clinics that treat patients with underlying immune deficiencies. These relationships help inform real world usage and support ongoing safety and effectiveness monitoring of its products. In addition Invivyd collaborates with patient advocacy groups to raise awareness about preventive options for immunocompromised individuals. The company collects feedback from treating physicians to refine its medical affairs and outreach efforts.

Investment Thesis

▲ Bull case

Invivyd's ability to accelerate DECLARATION study enrollment beyond internal expectations despite intentional pacing for seasonal alignment demonstrates strong underlying demand for its VYD2311 candidate, with management noting recruitment resumed at full speed and remains on track for timely completion, signaling confidence in trial execution and reducing the risk of delays that could impede regulatory timelines, while the Independent Data Monitoring Committee's recommendation to reduce post-dose monitoring from two hours to thirty minutes serves as an early validation of the product's favorable safety and tolerability profile, which could translate into broader clinical adoption and real-world usability advantages over vaccine-based alternatives requiring longer observation periods.
The company's disclosed expansion of its early discovery pipeline to include monoclonal antibody candidates targeting measles, mumps, rubella, Lyme disease, and additional pathogens represents a structural shift beyond its current COVID-19 focus, creating a diversified pipeline that could reduce reliance on any single infectious disease market and position Invivyd as a broad-spectrum monoclonal antibody platform with long-term value creation potential, especially as these candidates target high-burden, vaccine-preventable, or chronic conditions where existing prophylactic or therapeutic options may be suboptimal.
PEMGARDA's 22% year-over-year revenue growth in Q1 2026, achieved despite typical seasonal declines in infectious disease products and without heavy promotion from management, reflects underlying resilience in demand driven by vulnerable populations making rational, risk-based decisions amid persistent low-level SARS-CoV-2 circulation, suggesting that the commercial infrastructure built for PEMGARDA is not only sustainable but transferable to VYD2311 upon approval, thereby de-risking future commercialization efforts and providing a near-term revenue bridge to support R&D investment.
The "antibodies for anybody" direct-to-consumer campaign featuring Lindsay Vonn, though still in its infancy, is generating initial public attention and serves as an underappreciated catalyst for scaling immunology education, which could foster greater public acceptance of monoclonal antibodies as a preventive tool, particularly among vaccine-hesitant demographics who, per Dr. Mina's insights, are not inherently anti-medicine but react to symptom burden—a dynamic that could unlock underserved markets if VYD2311's low reactogenicity profile is effectively communicated.
Increased government affairs engagement in Washington, D.C., particularly around educating policymakers on monoclonal antibody approaches for public health, reflects a strategic effort to shape future infectious disease policy in a way that could favorably influence procurement guidelines, emergency use authorizations, or public health recommendations for antibody-based prophylaxis, creating a potential regulatory tailwind that management did not emphasize but could significantly expand addressable markets beyond traditional vaccine-centric frameworks.

Invivyd's ability to accelerate DECLARATION study enrollment beyond internal expectations despite intentional pacing for seasonal alignment demonstrates strong underlying demand for its VYD2311 candidate, with management noting recruitment resumed at full speed and remains on track for timely completion, signaling confidence in trial execution and reducing the risk of delays that could impede regulatory timelines, while the Independent Data Monitoring Committee's recommendation to reduce post-dose monitoring from two hours to thirty minutes serves as an early validation of the product's favorable safety and tolerability profile, which could translate into broader clinical adoption and real-world usability advantages over vaccine-based alternatives requiring longer observation periods.
The company's disclosed expansion of its early discovery pipeline to include monoclonal antibody candidates targeting measles, mumps, rubella, Lyme disease, and additional pathogens represents a structural shift beyond its current COVID-19 focus, creating a diversified pipeline that could reduce reliance on any single infectious disease market and position Invivyd as a broad-spectrum monoclonal antibody platform with long-term value creation potential, especially as these candidates target high-burden, vaccine-preventable, or chronic conditions where existing prophylactic or therapeutic options may be suboptimal.
PEMGARDA's 22% year-over-year revenue growth in Q1 2026, achieved despite typical seasonal declines in infectious disease products and without heavy promotion from management, reflects underlying resilience in demand driven by vulnerable populations making rational, risk-based decisions amid persistent low-level SARS-CoV-2 circulation, suggesting that the commercial infrastructure built for PEMGARDA is not only sustainable but transferable to VYD2311 upon approval, thereby de-risking future commercialization efforts and providing a near-term revenue bridge to support R&D investment.
The "antibodies for anybody" direct-to-consumer campaign featuring Lindsay Vonn, though still in its infancy, is generating initial public attention and serves as an underappreciated catalyst for scaling immunology education, which could foster greater public acceptance of monoclonal antibodies as a preventive tool, particularly among vaccine-hesitant demographics who, per Dr. Mina's insights, are not inherently anti-medicine but react to symptom burden—a dynamic that could unlock underserved markets if VYD2311's low reactogenicity profile is effectively communicated.
Increased government affairs engagement in Washington, D.C., particularly around educating policymakers on monoclonal antibody approaches for public health, reflects a strategic effort to shape future infectious disease policy in a way that could favorably influence procurement guidelines, emergency use authorizations, or public health recommendations for antibody-based prophylaxis, creating a potential regulatory tailwind that management did not emphasize but could significantly expand addressable markets beyond traditional vaccine-centric frameworks.

▼ Bear case

Despite management's optimistic framing of the IDMC's recommendation to reduce post-dose monitoring from two hours to thirty minutes as an encouraging safety signal, the change remains a protocol adjustment within an ongoing pivotal study and does not yet constitute regulatory validation or labeling inclusion, meaning its real-world impact on adoption, clinician confidence, or reimbursement pathways remains uncertain and could be overstated, particularly if future safety data from the full DECLARATION cohort reveals unexpected adverse events that necessitate a reversal of this leniency.
While PEMGARDA achieved 22% year-over-year revenue growth in Q1 2026, this performance occurred against a unusually weak prior-year period marked by seasonal drop-offs and pandemic-related demand volatility, and the growth rate may not be sustainable as the base effect diminishes, especially if SARS-CoV-2 transmission patterns evolve toward endemicity with lower hospitalization rates, reducing the perceived urgency for prophylactic monoclonal antibodies among vulnerable populations who currently drive demand.
The expansion of the early discovery pipeline into measles, mumps, rubella, Lyme disease, and other pathogens, while scientifically ambitious, remains at a preclinical or discovery stage with no disclosed timelines, preclinical data, or partnership arrangements, rendering these programs highly speculative and distant from near-term revenue contribution, thereby risking investor expectations being inflated by long-term pipeline potential that may never materialize due to scientific, manufacturing, or regulatory hurdles inherent in monoclonal antibody development for novel targets.
The "antibodies for anybody" direct-to-consumer campaign, despite generating initial public attention, lacks measurable metrics on engagement, conversion, or educational impact, and its reliance on celebrity endorsement without clear ties to medical education infrastructure raises questions about its scalability and cost-effectiveness, particularly if it fails to translate awareness into tangible demand for VYD2311 or shifts in public health behavior, making it a potentially costly diversion of SG&A resources with uncertain return on investment.
Management's heightened government affairs activity in Washington, D.C., while framed as educational and advocacy-driven, does not disclose specific policy asks, legislative tracking, or measurable outcomes, leaving unclear whether these efforts are yielding tangible influence on infectious disease policy or merely represent increased overhead with minimal strategic return, especially given the complexity of shifting entrenched vaccine-centric public health paradigms in a politically polarized environment.

Despite management's optimistic framing of the IDMC's recommendation to reduce post-dose monitoring from two hours to thirty minutes as an encouraging safety signal, the change remains a protocol adjustment within an ongoing pivotal study and does not yet constitute regulatory validation or labeling inclusion, meaning its real-world impact on adoption, clinician confidence, or reimbursement pathways remains uncertain and could be overstated, particularly if future safety data from the full DECLARATION cohort reveals unexpected adverse events that necessitate a reversal of this leniency.
While PEMGARDA achieved 22% year-over-year revenue growth in Q1 2026, this performance occurred against a unusually weak prior-year period marked by seasonal drop-offs and pandemic-related demand volatility, and the growth rate may not be sustainable as the base effect diminishes, especially if SARS-CoV-2 transmission patterns evolve toward endemicity with lower hospitalization rates, reducing the perceived urgency for prophylactic monoclonal antibodies among vulnerable populations who currently drive demand.
The expansion of the early discovery pipeline into measles, mumps, rubella, Lyme disease, and other pathogens, while scientifically ambitious, remains at a preclinical or discovery stage with no disclosed timelines, preclinical data, or partnership arrangements, rendering these programs highly speculative and distant from near-term revenue contribution, thereby risking investor expectations being inflated by long-term pipeline potential that may never materialize due to scientific, manufacturing, or regulatory hurdles inherent in monoclonal antibody development for novel targets.
The "antibodies for anybody" direct-to-consumer campaign, despite generating initial public attention, lacks measurable metrics on engagement, conversion, or educational impact, and its reliance on celebrity endorsement without clear ties to medical education infrastructure raises questions about its scalability and cost-effectiveness, particularly if it fails to translate awareness into tangible demand for VYD2311 or shifts in public health behavior, making it a potentially costly diversion of SG&A resources with uncertain return on investment.
Management's heightened government affairs activity in Washington, D.C., while framed as educational and advocacy-driven, does not disclose specific policy asks, legislative tracking, or measurable outcomes, leaving unclear whether these efforts are yielding tangible influence on infectious disease policy or merely represent increased overhead with minimal strategic return, especially given the complexity of shifting entrenched vaccine-centric public health paradigms in a politically polarized environment.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	68,334.77 Bn	-31.89 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,887.92 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,132.35 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	475.16 Bn	0.00 Bn	82.79	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	122.97 Bn	0.00 Bn	10.07	-
6	REGN	Regeneron Pharmaceuticals, Inc.	69.33 Bn	0.00 Bn	4.65	1.99 Bn
7	BLTE	Belite Bio, Inc	62.61 Bn	368.28 Bn	-	-
8	ARGX	Argenx Se	57.10 Bn	0.00 Bn	10.84	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password